Home | Welcome to Contract Pharma   
Last Updated Friday, April 18 2014
Print

AnaptysBio, Momenta Enter Antibody Development Pact



By Kristin Brooks



Published December 17, 2013
Related Searches: Development
AnaptysBio, Inc. has initiated an antibody development program with Momenta Pharmaceuticals focused on the development of novel antibodies against an undisclosed target. AnaptysBio will receive an upfront fee in exchange for an option to acquire antibodies generated using its SHM-XEL platform against a specific therapeutic target. Financial terms were not disclosed.
 
"AnaptysBio's platform technology and antibody development capabilities have been strongly validated by numerous successful partnerships," said Hamza Suria, AnaptysBio's president and chief executive officer. "We look forward to working with Momenta on the development of these exciting new antibodies for unmet medical needs."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On